Leaders in Microfluidics & MEMS

 

Microfluidics, in which minute volumes of fluids are processed for analysis, has the potential to significantly speed screening for a variety of life science and medical conditions by enabling testing directly at point-of-care or at home. Additionally, epidemiology is driving development of inexpensive microfluidic testing devices for rapid onsite analysis in the field.

Many applications are mature, and new applications are being developed. Current commercial technologies include drug delivery systems, drug detection, and circulating tumor cell detection (CTC). 

Microfluidics and related technology can offer size reduction of test equipment at a microelectronic scale, enabling portable and even handheld testing and diagnosis wherever and whenever it is needed. 

 

Most everything we know about fluids is based on macroscale observation. Things are different at the microscale, where "channels" can be built with two walls instead of four, turbulence doesn't exist, and fluids can flow side by side without mixing.

Microfluidics Challenges

 

However, microfluidics engineering and product development for life sciences pose many challenges. The technology is complex, requiring reliable integration of microfluidic flows with chemical reagents as well as integrated circuits and miniature etched devices (called MEMS, or micro-electromechanical systems) that may include pumps or valves.

 

Real-world samples can often be viscous, prone to bubble formation, and contain particles that can clog microchannels. In addition, for many applications, the volume of the sample needs to be large enough to have clinical relevance. 

 

Micropoint: Healthier Living through Microfluidics Leadership

The Micropoint technology team has resolved these challenges. Bringing together experts in biochemistry, microfluidics, nanotechnology, MEMS and semiconductor engineering, the company has successfully developed highly accurate diagnostic products that provide results within minutes at the point-of-care or patient bedside, for multiple medical domains

 

Micropoint continues to build on its strong IP portfolio and know-how. Besides microfluidic control devices for the mLabs® platform, the team most recently miniaturized the advanced technology for its handheld qLabs® wireless testing platform.

The Path to Improved Outcomes Worldwide

According to the National Institutes of Health, microfluidics presents several advantages compared with existing lateral flow Immunoassay (LFIA) technologies. These include the ability for extensive use of complex multiplexing approaches and formats, the capacity for inclusion of sequential sample pre-conditioning steps of different types, reagent storage, the use of multiple steps involving reagent addition, mixing and washing, the potential for incorporation of centrifugal steps at various speeds, and the application of a range of detection strategies leading to greater sensitivity and clarity of results.

 

Micropoint's next-generation microfluidic cartridge will feature dynamic flow control, a high-sensitivity diagnostic biocard, and a multichannel and multiplexing system.

 

 

Micropoint Bioscience: leaders in microfluidic technology and development

 

 

U.S. Headquarters

 

Micropoint Bioscience, Inc.
3521 Leonard Court 
Santa Clara, CA 95054
United States

 

T:+1 (408) 588-1682
F:+1 (408) 588-1620

 

 

European Office

 

Micropoint Bioscience, Inc.

2 rue Eugene Sue

38100 Grenoble

France 

 

T: +33 6 22 38 20 48

F: +33 4 76 09 03 50

Asian Office

 

Micropoint Biotechnologies Co., Ltd.

5F, Bldg 1

Runheng Dingfeng Industrial Park, Liuxian 2 Rd.

Shenzhen 518101, Guangdong

China

 

T: +86 755 21600849

F: +86 755 86673903

Copyright Micropoint Biosciences 2016

Micropoint Bioscience products are not available for sale nor marketed in the United States at this time.